Background: It is controversial whether the apolipoprotein E epsilon 4 allele (APOE ε4) is a risk gene for human immunodeficiency virus (HIV)-related neurocognitive impairment. This meta-analysis aimed to summarize e...Background: It is controversial whether the apolipoprotein E epsilon 4 allele (APOE ε4) is a risk gene for human immunodeficiency virus (HIV)-related neurocognitive impairment. This meta-analysis aimed to summarize evidence of the associations betweenAPOE ε4 and cognitive impairment in people living with HIV (PLWH).Methods: Our study conducted a systematic literature search of PubMed, Web of Science, Embase, Google Scholar, and ProQuest for studies published before April 11, 2022 that evaluated associations betweenAPOE ε4 and cognitive impairment in adult PLWH (aged ≥18 years). We calculated pooled odds ratios (ORs) of global cognitive impairment and 95% confidence intervals (CIs) and standardized mean differences (SMDs) for specific cognitive domains betweenAPOE ε4 carriers and non-carriers. Subgroup meta-analyses were used to evaluate the result profiles across different categorical variables.Results: Twenty studies met the inclusion criteria, including 19 that evaluated global cognitive impairment.APOE ε4 was significantly associated with global cognitive impairment in PLWH (OR = 1.36, 95% CI = [1.05, 1.78], number of estimates [k] = 19,P = 0.02, random effects). Subgroup meta-analysis based percentage of females showed evident intergroup differences in global cognitive performance between ε4 carriers and non-carriers (P = 0.015).APOE ε4 carriers had lower cognitive test scores than non-carriers in all seven cognitive domains, including fluency (SMD = -0.51, 95% CI = [-0.76, -0.25],P < 0.001,k = 4,I^(2)= 0%), learning (SMD = -0.52, 95% CI = [-0.75, -0.28],P < 0.001,k = 5,I^(2) = 0%), executive function (SMD = -0.41, 95% CI= [-0.59, -0.23],P < 0.001,k= 8,I^(2)= 0%), memory (SMD=-0.41, 95% CI= [-0.61, -0.20],P < 0.001,k= 10,I^(2)= 36%), attention/working memory (SMD=-0.34, 95% CI= [-0.54, -0.14],P= 0.001,k= 6,I^(2)= 0%), speed of information processing (SMD = -0.34, 95% CI = [-0.53, -0.16],P < 0.001,k = 8,I^(2) = 0%), and motor function (SMD = -0.19, 95% CI = [-0.38, -0.01],P = 0.04,k = 7,I^(2) = 0%).Conclusions: Our meta-analysis provides significant evidence thatAPOE ε4 is a risk genotype for HIV-associated cognitive impairment, especially in cognitive domains of fluency, learning, executive function, and memory. Moreover, the impairment is sex specific.Meta analysis registration: PROSPERO, CRD 42021257775.展开更多
基金This work was supported by grants from the National Natural Science Foundation of China (No. NSFC, 81974303)the High-Level Public Health Specialized Talents Project of Beijing Municipal Health Commission (Nos. 2022-1-007, 2022-2-018)+2 种基金the "Climbing the peak (Dengfeng) " Talent Training Program of Beijing Hospitals Authority (No. DFL20191701)the Beijing Health Technologies Promotion Program (No. BHTPP2020)and the Beijing Key Laboratory for HIV/AIDS Research (No. BZ0089) .
文摘Background: It is controversial whether the apolipoprotein E epsilon 4 allele (APOE ε4) is a risk gene for human immunodeficiency virus (HIV)-related neurocognitive impairment. This meta-analysis aimed to summarize evidence of the associations betweenAPOE ε4 and cognitive impairment in people living with HIV (PLWH).Methods: Our study conducted a systematic literature search of PubMed, Web of Science, Embase, Google Scholar, and ProQuest for studies published before April 11, 2022 that evaluated associations betweenAPOE ε4 and cognitive impairment in adult PLWH (aged ≥18 years). We calculated pooled odds ratios (ORs) of global cognitive impairment and 95% confidence intervals (CIs) and standardized mean differences (SMDs) for specific cognitive domains betweenAPOE ε4 carriers and non-carriers. Subgroup meta-analyses were used to evaluate the result profiles across different categorical variables.Results: Twenty studies met the inclusion criteria, including 19 that evaluated global cognitive impairment.APOE ε4 was significantly associated with global cognitive impairment in PLWH (OR = 1.36, 95% CI = [1.05, 1.78], number of estimates [k] = 19,P = 0.02, random effects). Subgroup meta-analysis based percentage of females showed evident intergroup differences in global cognitive performance between ε4 carriers and non-carriers (P = 0.015).APOE ε4 carriers had lower cognitive test scores than non-carriers in all seven cognitive domains, including fluency (SMD = -0.51, 95% CI = [-0.76, -0.25],P < 0.001,k = 4,I^(2)= 0%), learning (SMD = -0.52, 95% CI = [-0.75, -0.28],P < 0.001,k = 5,I^(2) = 0%), executive function (SMD = -0.41, 95% CI= [-0.59, -0.23],P < 0.001,k= 8,I^(2)= 0%), memory (SMD=-0.41, 95% CI= [-0.61, -0.20],P < 0.001,k= 10,I^(2)= 36%), attention/working memory (SMD=-0.34, 95% CI= [-0.54, -0.14],P= 0.001,k= 6,I^(2)= 0%), speed of information processing (SMD = -0.34, 95% CI = [-0.53, -0.16],P < 0.001,k = 8,I^(2) = 0%), and motor function (SMD = -0.19, 95% CI = [-0.38, -0.01],P = 0.04,k = 7,I^(2) = 0%).Conclusions: Our meta-analysis provides significant evidence thatAPOE ε4 is a risk genotype for HIV-associated cognitive impairment, especially in cognitive domains of fluency, learning, executive function, and memory. Moreover, the impairment is sex specific.Meta analysis registration: PROSPERO, CRD 42021257775.
